Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255593669> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4255593669 abstract "Aims:Filgotinib is a potent, oral, JAK1-preferential inhibitor for the treatment of rheumatoid arthritis (RA). This report describes exposure-response (ER) analyses of filgotinib for dose confirmation based on three Phase 3 and two Phase 2 studies in moderate to severe RA patients. Methods:The PK exposures used in ER analyses were derived from population pharmacokinetic analysis. The relationship between filgotinib exposures and various efficacy endpoints (ACR20/50/70 and DAS28) was assessed over octile groups of exposures by using combined exposures of filgotinib and GS-829845 (major, active metabolite). For the ER analyses of safety, exposures were examined between subjects who experienced and who did not experience the evaluated safety events, which was conducted separately for filgotinib and GS-829845. Results:Exposure efficacy relationships consistently revealed high response rates across the exposure range for filgotinib 200 mg once daily dose. A trend of increasing response with increasing exposure was observed over the exposure range for the primary and multiple secondary efficacy endpoints, with exposures associated with the 200 mg dose primarily residing on the curve plateau. For exposure-safety analyses, filgotinib and GS-829845 exposures were similar irrespective of presence/absence of the evaluated safety endpoints, indicating no exposure-safety relationship for common TEAEs, common laboratory abnormalities, serious TEAEs, or serious infections. Conclusions:ER analyses confirmed that filgotinib produced more robust therapeutic effects across the exposure range observed at 200 mg once daily compared to lower doses. The positive exposure-efficacy relationship and a lack of exposure-safety relationship on the evaluated safety endpoints supported the 200 mg once daily dose for commercialization." @default.
- W4255593669 created "2022-05-12" @default.
- W4255593669 creator A5001083964 @default.
- W4255593669 creator A5004508109 @default.
- W4255593669 creator A5013479458 @default.
- W4255593669 creator A5027087975 @default.
- W4255593669 creator A5041344161 @default.
- W4255593669 creator A5052133090 @default.
- W4255593669 creator A5059158287 @default.
- W4255593669 creator A5068470814 @default.
- W4255593669 creator A5076963248 @default.
- W4255593669 creator A5077361663 @default.
- W4255593669 creator A5088051469 @default.
- W4255593669 date "2021-06-20" @default.
- W4255593669 modified "2023-10-05" @default.
- W4255593669 title "Exposure-Response Relationships for Efficacy and Safety of Filgotinib and its metabolite GS-829845 in Subjects with Rheumatoid Arthritis Based on Phase 2 and Phase 3 Studies" @default.
- W4255593669 doi "https://doi.org/10.22541/au.162418885.56100410/v1" @default.
- W4255593669 hasPublicationYear "2021" @default.
- W4255593669 type Work @default.
- W4255593669 citedByCount "0" @default.
- W4255593669 crossrefType "posted-content" @default.
- W4255593669 hasAuthorship W4255593669A5001083964 @default.
- W4255593669 hasAuthorship W4255593669A5004508109 @default.
- W4255593669 hasAuthorship W4255593669A5013479458 @default.
- W4255593669 hasAuthorship W4255593669A5027087975 @default.
- W4255593669 hasAuthorship W4255593669A5041344161 @default.
- W4255593669 hasAuthorship W4255593669A5052133090 @default.
- W4255593669 hasAuthorship W4255593669A5059158287 @default.
- W4255593669 hasAuthorship W4255593669A5068470814 @default.
- W4255593669 hasAuthorship W4255593669A5076963248 @default.
- W4255593669 hasAuthorship W4255593669A5077361663 @default.
- W4255593669 hasAuthorship W4255593669A5088051469 @default.
- W4255593669 hasBestOaLocation W42555936691 @default.
- W4255593669 hasConcept C126322002 @default.
- W4255593669 hasConcept C197934379 @default.
- W4255593669 hasConcept C203092338 @default.
- W4255593669 hasConcept C2777575956 @default.
- W4255593669 hasConcept C535046627 @default.
- W4255593669 hasConcept C71924100 @default.
- W4255593669 hasConceptScore W4255593669C126322002 @default.
- W4255593669 hasConceptScore W4255593669C197934379 @default.
- W4255593669 hasConceptScore W4255593669C203092338 @default.
- W4255593669 hasConceptScore W4255593669C2777575956 @default.
- W4255593669 hasConceptScore W4255593669C535046627 @default.
- W4255593669 hasConceptScore W4255593669C71924100 @default.
- W4255593669 hasLocation W42555936691 @default.
- W4255593669 hasOpenAccess W4255593669 @default.
- W4255593669 hasPrimaryLocation W42555936691 @default.
- W4255593669 hasRelatedWork W1506200166 @default.
- W4255593669 hasRelatedWork W1995515455 @default.
- W4255593669 hasRelatedWork W2048182022 @default.
- W4255593669 hasRelatedWork W2080531066 @default.
- W4255593669 hasRelatedWork W2604872355 @default.
- W4255593669 hasRelatedWork W2748952813 @default.
- W4255593669 hasRelatedWork W2899084033 @default.
- W4255593669 hasRelatedWork W3031052312 @default.
- W4255593669 hasRelatedWork W3032375762 @default.
- W4255593669 hasRelatedWork W3108674512 @default.
- W4255593669 isParatext "false" @default.
- W4255593669 isRetracted "false" @default.
- W4255593669 workType "article" @default.